About Shionogi
Shionogi is a company based in New York (United States) founded in 1878. The company has 264 employees as of December 31, 2021. Shionogi has completed 2 acquisitions, including C & O Pharmaceutical Technology and Qpex Biopharma.
- Headquarter New York, United States
- Employees 264 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
264
as on Dec 31, 2021
-
Investments & Acquisitions
C & O Pharmaceutical Technology
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Shionogi
Unlock access to complete
Unlock access to complete
Leadership Team
54 people
Sales and Marketing
29 people
Software Development Team
22 people
Senior Team
20 people
Product Management Team
14 people
Legal and Compliance
9 people
Operations Team
9 people
Medical Team
8 people
Unlock access to complete
Funding Insights of Shionogi
Detailed funding history for Shionogi
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Shionogi
Shionogi has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include C & O Pharmaceutical Technology and Qpex Biopharma.
Investment portfolio details for Shionogi
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapies for infectious diseases are developed using beta-lactamase inhibitor technology.
|
Locked | Locked | 2018 | Locked | |
|
Aeronautical and maritime radiocommunication systems are designed and manufactured.
|
Locked | Locked | 1999 | Locked |
Complete acquisition details for Shionogi
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Shionogi
Detailed financials for Shionogi
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Shionogi Comparisons
Peer comparison for Shionogi
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Shionogi
Detailed competitors of Shionogi
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Shionogi
Complete news archive for Shionogi
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Shionogi
Shionogi was founded in 1878.
Shionogi is headquartered in New York, United States. It is registered at New York, New York, United States.
As of Dec 31, 2021, the latest employee count at Shionogi is 264.
Shionogi is engaged in developing and marketing a range of pharmaceutical and health maintenance products. Product categories include womens health, pain, anti-infectives, cardiovascular, pediatrics, and others. Products include Osphena (FDA approved for moderate to severe painful sex after menopause), Xodol (Pain), Doribax (Anti-Infective), Fortamet (Hyperglycemia), Solar (Blood Pressure) and Methylin (CNS stimulant). The company also claims to have a pipeline of drugs for the treatment of infection, pain, womens health, rhinitis, cancer, and HIV. In 2022, the company recorded annual revenues of 3.45B and a net profit of 1.53B.
Shionogi has made 2 acquisitions, including C & O Pharmaceutical Technology, and Qpex Biopharma.